Buprenorphine; Oxycodone + Naloxone
Deferred PainNot applicable
Additional strengths for management of pain (buprenorphine patches) and non-cancer pain (oxycodone + naloxone tablets).
1
Submissions
1 resub
2015–15
On the record
—
ICER range
Not modelled
Cost basis
From the public summary
PBAC outcome
3.1 The PBAC deferred making a recommendation regarding the proposed General Schedule listing of additional buprenorphine patch strengths.PSD · Jul 2015
3.2 The PBAC deferred making a recommendation regarding the proposed General Schedule listing of additional oxycodone + naloxone tablet strengths.PSD · Jul 2015
Cost-effectiveness
Minor submissions; no economic evaluation conducted.
Decision context
PopulationPatients requiring buprenorphine patches at higher doses and patients requiring oxycodone + naloxone at varying strengths for pain management, including elderly patients with musculoskeletal pain and those in palliative/oncological settings.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2015 | Deferred | — | — | Other |
Similar precedents
Oxycodone Hydrochloride + Naloxone Hydrochloride78%Buprenorphine77%Buprenorphine + Naloxone76%Buprenorphine Hydrochloride With Naloxone Hydrochloride74%Buprenorphine, Buprenorphine With Naloxone, Methadone73%Oxycodone With Naloxone74%Oxycodone, Tramadol, Codeine, Hydromorphone, Morphine, Tapentadol, Buprenorphine, Fentanyl74%Buprenorphine With Naloxone71%